Program Schedule

1461
Testing of Cerebrospinal Fluid 1,3 Beta-D-Glucan for the Diagnosis of Fungal Meningitis Associated with Contaminated Methylprednisolone Injections

Session: Poster Abstract Session: Fungal Infections
Saturday, October 11, 2014
Room: The Pennsylvania Convention Center: IDExpo Hall BC
Posters
  • CSFBDG_finalposter.pdf (461.8 kB)
  • Background:

    The prompt diagnosis and treatment of fungal meningitis is critical, but culture is insensitive.  (1,3)-beta-D-glucan (BDG) is FDA-cleared for serologic diagnosis of invasive fungal disease.  (Fungitell assay, Associates of Cape Cod Incorporated).  However, BDG is not cleared for testing cerebrospinal fluid (CSF) and the appropriate cutoff is unknown.  We aim to validate the accuracy of CSF BDG for the diagnosis of fungal meningitis among patients exposed to contaminated methylprednisolone acetate (MPA).        

    Methods:

    A case-control study was conducted at St. Joseph Mercy Hospital and Vanderbilt University from November, 2013 February, 2014.  Patients were included if they received a contaminated MPA injection.  Cases were classified as probable or confirmed meningitis according to Centers for Disease Control and Prevention guidelines.  Controls were defined as persons exposed but not diagnosed with diseaseCSF BDG testing was performed according to the package insert for serum and validated using Clinical Laboratory Standards Institute procedures (MiraVista Diagnostics).

    Results:

    Of 233 patients, 45 had meningitis (28 confirmed), 53 had spinal/paraspinal infection (19 confirmed), and 135 did not develop disease.  The figure depicts CSF BDG results from those with confirmed meningitis, probable meningitis, and controls.  Using the manufacturer's cutoff (BDG ≥ 80 pg/mL), the sensitivity and specificity were 96% (95% CI 80-100%) and 93% (95% CI 87-97%) for confirmed meningitis and 84% (95% CI 70-93%) and 93% (95% CI 87-97%) for probable meningitis.  The Receiver Operating Characteristic analysis identified the optimal cutoff for confirmed meningitis to be ≥ 500 pg/mL (sensitivity 93% [95% CI 76-99%], specificity 100% [95% CI 97-100%]); for probable meningitis to be 66 pg/mL (sensitivity 91% [95% CI 79-98%],specificity 92% [95% CI 87-96%]).

    Conclusion:

    Our results suggest that CSF BDG is both a highly sensitive and specific test for diagnosis of fungal meningitis associated with contaminated MPA injections.  Further study is needed on the diagnostic utility of CSF BDG for other types of fungal meningitis.    

     - Description: IDWeek_BDG_figure.jpg

     

    Anurag Malani, MD1, Bonita Singal, MD, PhD2, Lawrence Wheat, MD3, Ola Al Sous, MD4, Theresa Summons, MLS5, Michelle Durkin, MS3 and April Pettit, MD, MPH6, (1)St. Joseph Mercy Health System, Ypsilanti, MI, (2)St. Joseph Mercy Hospital, Ann Arbor, MI, (3)MiraVista Diagnostics, Indianapolis, IN, (4)St. Joseph Mercy Hospital, Ypsilanti, MI, (5)Clinical, MiraVista Diagnostics, Indianapolis, IN, (6)Division of Infectious Diseases, Vanderbilt University, Nashville, TN

    Disclosures:

    A. Malani, None

    B. Singal, None

    L. Wheat, MiraVista Diagnostics: Employee, Salary

    O. Al Sous, None

    T. Summons, MiraVista Diagnostics: Employee, Salary

    M. Durkin, MiraVista Diagnostics: Employee, Salary

    A. Pettit, None

    See more of: Fungal Infections
    See more of: Poster Abstract Session

    Findings in the abstracts are embargoed until 12:01 a.m. EDT, Oct. 8th with the exception of research findings presented at the IDWeek press conferences.

    Sponsoring Societies:

    © 2014, idweek.org. All Rights Reserved.

    Follow IDWeek